Health Care & Life Sciences » Pharmaceuticals | Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc. Cl A | Mutual Funds

Mutual Funds that own Ironwood Pharmaceuticals Inc. Cl A

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Growth Company Fund
4,870,533
3.5%
-26,428
0.19%
07/31/2018
Vanguard Health Care Fund
4,594,407
3.3%
0
0.18%
06/30/2018
Fidelity Select Biotechnology Portfolio
3,802,820
2.73%
0
0.8%
07/31/2018
Hartford Mid Cap Fund
3,714,480
2.67%
0
0.54%
07/31/2018
Vanguard Total Stock Market Index Fund
3,482,156
2.5%
4,554
0.01%
07/31/2018
Vanguard Small Cap Index Fund
3,472,402
2.5%
47,733
0.07%
07/31/2018
SPDR S&P Biotech ETF
3,086,935
2.22%
7,941
1.01%
09/06/2018
Janus Triton Fund
3,049,863
2.19%
0
0.5%
06/30/2018
Brown Capital Management - Small Company Fund
2,997,208
2.15%
0
1.06%
03/31/2018
iShares Russell 2000 ETF
2,953,139
2.12%
-1,578
0.12%
09/06/2018

About Ironwood Pharmaceuticals

View Profile
Address
301 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.ironwoodpharma.com
Updated 07/08/2019
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.